Halozyme Therapeutics Inc. (NASDAQ:HALO)‘s stock had its “sell” rating restated by investment analysts at Jefferies Group in a research report issued to clients and investors on Tuesday. They presently have a $6.75 price objective on the biopharmaceutical company’s stock. Jefferies Group’s price objective suggests a potential downside of 48.04% from the stock’s current price.
HALO has been the topic of several other research reports. Wells Fargo & Co. reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday, September 8th. Piper Jaffray Cos. upped their price objective on shares of Halozyme Therapeutics from $15.00 to $18.00 and gave the company an “overweight” rating in a report on Friday, September 16th. Finally, Deutsche Bank AG initiated coverage on shares of Halozyme Therapeutics in a report on Thursday, November 3rd. They set a “buy” rating and a $12.00 price objective on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the stock. Halozyme Therapeutics currently has a consensus rating of “Buy” and an average target price of $13.96.
Shares of Halozyme Therapeutics (NASDAQ:HALO) traded up 2.69% during midday trading on Tuesday, hitting $12.99. The stock had a trading volume of 800,356 shares. The company’s market cap is $1.66 billion. Halozyme Therapeutics has a 52 week low of $6.96 and a 52 week high of $18.39. The stock’s 50-day moving average price is $10.70 and its 200 day moving average price is $10.10.
Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.04. Halozyme Therapeutics had a negative net margin of 44.60% and a negative return on equity of 405.28%. The firm had revenue of $31.90 million for the quarter, compared to analyst estimates of $34.43 million. During the same quarter in the prior year, the business earned ($0.19) earnings per share. The business’s quarterly revenue was up 53.4% compared to the same quarter last year. On average, equities analysts forecast that Halozyme Therapeutics will post ($0.87) earnings per share for the current year.
Large investors have recently bought and sold shares of the stock. Commonwealth Equity Services Inc purchased a new stake in Halozyme Therapeutics during the second quarter valued at approximately $109,000. BNP Paribas Arbitrage SA raised its stake in Halozyme Therapeutics by 113.7% in the third quarter. BNP Paribas Arbitrage SA now owns 9,051 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 4,815 shares during the period. Amalgamated Bank raised its stake in Halozyme Therapeutics by 3.0% in the second quarter. Amalgamated Bank now owns 11,518 shares of the biopharmaceutical company’s stock valued at $117,000 after buying an additional 338 shares during the period. Royal Bank of Canada raised its stake in Halozyme Therapeutics by 13.5% in the second quarter. Royal Bank of Canada now owns 14,200 shares of the biopharmaceutical company’s stock valued at $122,000 after buying an additional 1,685 shares during the period. Finally, Parametrica Management Ltd purchased a new stake in Halozyme Therapeutics during the third quarter valued at approximately $131,000. Hedge funds and other institutional investors own 81.45% of the company’s stock.
Halozyme Therapeutics Company Profile